Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Leonard, KA; Deisseroth, AB; Austin, DJ
   Combinatorial chemistry in cancer drug development
   CANCER JOURNAL
   
   K.A. Leonard et al., "Combinatorial chemistry in cancer drug development", CANCER J, 7(1), 2001, pp. 79-83
2. White, R; Rusconi, C; Scardino, E; Wolberg, A; Lawson, J; Hoffman, M; Sullenger, B
   Generation of species cross-reactive aptamers using "toggle" SELEX
   MOLECULAR THERAPY
   
   R. White et al., "Generation of species cross-reactive aptamers using "toggle" SELEX", MOL THER, 4(6), 2001, pp. 567-574
3. Sponer, G
   Prolongation of repolarization in pre-clinical investigations and phase I/II clinical trials: what should be done?
   EUROPEAN HEART JOURNAL SUPPLEMENTS
   
   G. Sponer, "Prolongation of repolarization in pre-clinical investigations and phase I/II clinical trials: what should be done?", EUR H J SUP, 3(K), 2001, pp. K101-K104
4. Morganroth, J
   Focus on issues in measuring and interpreting changes in the QTc interval duration
   EUROPEAN HEART JOURNAL SUPPLEMENTS
   
   J. Morganroth, "Focus on issues in measuring and interpreting changes in the QTc interval duration", EUR H J SUP, 3(K), 2001, pp. K105-K111
5. Bonnekoh, B; Bockelmann, R; Ambach, A; Gollnick, H
   Dithranol and dimethylfumarate suppress the interferon-gamma-induced up-regulation of cytokeratin 17 as a putative psoriasis autoantigen in vitro
   SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY
   
   B. Bonnekoh et al., "Dithranol and dimethylfumarate suppress the interferon-gamma-induced up-regulation of cytokeratin 17 as a putative psoriasis autoantigen in vitro", SKIN PH APP, 14(4), 2001, pp. 217-225
6. Winstanley, P
   Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria
   TROPICAL MEDICINE & INTERNATIONAL HEALTH
   
   P. Winstanley, "Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria", TR MED I H, 6(11), 2001, pp. 952-954
7. Emre, M; Qizilbash, N
   Experimental approaches and drugs in development for the treatment of dementia
   EXPERT OPINION ON INVESTIGATIONAL DRUGS
   
   M. Emre e N. Qizilbash, "Experimental approaches and drugs in development for the treatment of dementia", EXPERT OP I, 10(4), 2001, pp. 607-617
8. Ahmad, N; Adhami, VM; Afaq, F; Feyes, DK; Mukhtar, H
   Resveratrol causes WAF-l/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells
   CLINICAL CANCER RESEARCH
   
   N. Ahmad et al., "Resveratrol causes WAF-l/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells", CLIN CANC R, 7(5), 2001, pp. 1466-1473
9. Moresco, RM; Messa, C; Lucignani, G; Rizzo, G; Todde, S; Gilardi, MC; Grimaldi, A; Fazio, F
   Pet in psychopharmacology
   PHARMACOLOGICAL RESEARCH
   
   R.M. Moresco et al., "Pet in psychopharmacology", PHARMAC RES, 44(3), 2001, pp. 151-159
10. Barrow, JC; Nantermet, PG; Selnick, HG; Glass, KL; Ngo, PL; Young, MB; Pellicore, JM; Breslin, MJ; Hutchinson, JH; Freidinger, RM; Condra, C; Karczewski, J; Bednar, RA; Gaul, SL; Stern, A; Gould, R; Connolly, TM
    Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    
    J.C. Barrow et al., "Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists", BIOORG MED, 11(20), 2001, pp. 2691-2696
11. Garner, P; Sherry, B; Moilanen, S; Huang, YM
    In vitro stability of alpha-helical peptide nucleic acids (alpha PNAs)
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    
    P. Garner et al., "In vitro stability of alpha-helical peptide nucleic acids (alpha PNAs)", BIOORG MED, 11(17), 2001, pp. 2315-2317
12. Schellens, JHM; Dombernowsky, P; Cassidy, J; Epelbaum, R; Dirix, L; Cox, EH; Wanders, J; Calabresi, F; Paridaens, R; Monfardini, S; Wolff, J; Loos, WJ; Verweij, J; Pavlidis, N; Hanauske, AR
    Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9
    ANTI-CANCER DRUGS
    
    J.H.M. Schellens et al., "Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9", ANTI-CANC D, 12(7), 2001, pp. 583-590
13. Witte, MC; Montcouquiol, M; Corwin, JT
    Regeneration in avian hair cell epithelia: identification of intracellularsignals required for S-phase entry
    EUROPEAN JOURNAL OF NEUROSCIENCE
    
    M.C. Witte et al., "Regeneration in avian hair cell epithelia: identification of intracellularsignals required for S-phase entry", EUR J NEURO, 14(5), 2001, pp. 829-838
14. Raza, M; Shaheen, F; Choudhary, M; Suria, A; Atta-ur-Rahman; Sombati, S; DeLorenzo, RJ
    Anticonvulsant activities of the FS-1 subfraction isolated from roots of Delphinium denudatum
    PHYTOTHERAPY RESEARCH
    
    M. Raza et al., "Anticonvulsant activities of the FS-1 subfraction isolated from roots of Delphinium denudatum", PHYTOTHER R, 15(5), 2001, pp. 426-430
15. Lehr, CM
    In vitro intestinal and alveolar epithelium cultures in drug research
    ALTEX-ALTERNATIVEN ZU TIEREXPERIMENTEN
    
    C.M. Lehr, "In vitro intestinal and alveolar epithelium cultures in drug research", ALTEX-AL TI, 18(1), 2001, pp. 59-63
16. Lo, D; Hilbush, B; Sutcliffe, JG
    TOGA analysis of gene expression to accelerate target development
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
    
    D. Lo et al., "TOGA analysis of gene expression to accelerate target development", EUR J PH SC, 14(3), 2001, pp. 191-196
17. Gomeni, R; Bani, M; D'Angeli, C; Corsi, M; Bye, A
    Computer-assisted drug development (CADD): an emerging technology for designing first-time-in-man and proof-of-concept studies from preclinical experiments
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
    
    R. Gomeni et al., "Computer-assisted drug development (CADD): an emerging technology for designing first-time-in-man and proof-of-concept studies from preclinical experiments", EUR J PH SC, 13(3), 2001, pp. 261-270
18. Aarons, L; Karlsson, MO; Mentre, F; Rombout, F; Steimer, JL; van Peer, A
    Role of modelling and simulation in Phase I drug development
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
    
    L. Aarons et al., "Role of modelling and simulation in Phase I drug development", EUR J PH SC, 13(2), 2001, pp. 115-122
19. Bialer, M; Johannessen, SI; Kupferberg, HJ; Levy, RH; Loiseau, P; Perucca, E
    Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)
    EPILEPSY RESEARCH
    
    M. Bialer et al., "Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)", EPILEPSY R, 43(1), 2001, pp. 11-58
20. Hergovich, N; Singer, E; Agneter, E; Eichler, HG; Graselli, U; Simhandl, C; Jilma, B
    Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men: A randomized, double-blind, placebo-controlled trial
    NEUROPSYCHOPHARMACOLOGY
    
    N. Hergovich et al., "Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men: A randomized, double-blind, placebo-controlled trial", NEUROPSYCH, 24(5), 2001, pp. 590-593
21. Zhou, J; Riley, CM; Schowen, RL
    In vitro metabolism studies of the prodrug, 2 ',3 ',5 '-triacetyl-6-azauridine, utilizing an automated analytical system
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    
    J. Zhou et al., "In vitro metabolism studies of the prodrug, 2 ',3 ',5 '-triacetyl-6-azauridine, utilizing an automated analytical system", J PHARM B, 26(5-6), 2001, pp. 701-716
22. Miller, KJ; Bowsher, RR; Celniker, A; Gibbons, J; Gupta, S; Lee, JW; Swanson, SJ; Smith, WC; Weiner, RS
    Workshop on bioanalytical methods validation for macromolecules: Summary report
    PHARMACEUTICAL RESEARCH
    
    K.J. Miller et al., "Workshop on bioanalytical methods validation for macromolecules: Summary report", PHARM RES, 18(9), 2001, pp. 1373-1383
23. Papac, DI; Shahrokh, Z
    Mass spectrometry innovations in drug discovery and development
    PHARMACEUTICAL RESEARCH
    
    D.I. Papac e Z. Shahrokh, "Mass spectrometry innovations in drug discovery and development", PHARM RES, 18(2), 2001, pp. 131-145
24. Raza, M; Shaheen, F; Choudhary, MI; Sombati, S; Rafiq, A; Suria, A; Rahman, A; DeLorenzo, RJ
    Anticonvulsant activities of ethanolic extract and aqueous fraction isolated from Delphinium denudatum
    JOURNAL OF ETHNOPHARMACOLOGY
    
    M. Raza et al., "Anticonvulsant activities of ethanolic extract and aqueous fraction isolated from Delphinium denudatum", J ETHNOPHAR, 78(1), 2001, pp. 73-78
25. Hartvig, P; Bergstrom, M; Langstrom, B
    Use of positron emission tomography in analysing receptor function in vivo
    TOXICOLOGY LETTERS
    
    P. Hartvig et al., "Use of positron emission tomography in analysing receptor function in vivo", TOX LETT, 120(1-3), 2001, pp. 243-251
26. Newman, RA; Yang, J; Finlay, MRV; Cabral, F; Vourloumis, D; Stephens, LC; Troncoso, P; Wu, XB; Logothetis, CJ; Nicolaou, KC; Navone, NM
    Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    R.A. Newman et al., "Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts", CANC CHEMOT, 48(4), 2001, pp. 319-326
27. Saijo, N; Tamura, T; Yamamoto, N; Nishio, K
    New strategies for cancer therapy in the 21st century
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    N. Saijo et al., "New strategies for cancer therapy in the 21st century", CANC CHEMOT, 48, 2001, pp. S102-S106
28. Sheth, SB; DiCicco, RA; Hursting, MJ; Montague, T; Jorkasky, DK
    Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin
    THROMBOSIS AND HAEMOSTASIS
    
    S.B. Sheth et al., "Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin", THROMB HAEM, 85(3), 2001, pp. 435-440
29. Hasbargen, U; Reber, D; Versmold, H; Schulze, A
    Growth and development of children to 4 years of age after repeated antenatal steroid administration
    EUROPEAN JOURNAL OF PEDIATRICS
    
    U. Hasbargen et al., "Growth and development of children to 4 years of age after repeated antenatal steroid administration", EUR J PED, 160(9), 2001, pp. 552-555
30. Grahnen, A; Karlsson, MO
    Concentration-controlled or effect-controlled trials - Useful alternativesto conventional dose-controlled trials?
    CLINICAL PHARMACOKINETICS
    
    A. Grahnen e M.O. Karlsson, "Concentration-controlled or effect-controlled trials - Useful alternativesto conventional dose-controlled trials?", CLIN PHARMA, 40(5), 2001, pp. 317-325
31. Bellissant, E; Giudicelli, JF
    Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    E. Bellissant e J.F. Giudicelli, "Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients", BR J CL PH, 52(1), 2001, pp. 25-33
32. Jonsson, E; Friberg, LE; Karlsson, MO; Hassan, SB; Nygren, P; Kristensen, J; Tholander, B; Binderup, L; Larsson, R
    In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients
    CANCER LETTERS
    
    E. Jonsson et al., "In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients", CANCER LETT, 162(2), 2001, pp. 193-200
33. Shapiro, HM
    Multiparameter flow cytometry of bacteria: Implications for diagnostics and therapeutics
    CYTOMETRY
    
    H.M. Shapiro, "Multiparameter flow cytometry of bacteria: Implications for diagnostics and therapeutics", CYTOMETRY, 43(3), 2001, pp. 223-226
34. Taylor, JLS; Rabe, T; McGaw, LJ; Jager, AK; van Staden, J
    Towards the scientific validation of traditional medicinal plants
    PLANT GROWTH REGULATION
    
    J.L.S. Taylor et al., "Towards the scientific validation of traditional medicinal plants", PLANT GR R, 34(1), 2001, pp. 23-37
35. Agerso, H; Ynddal, L; Sogaard, B; Zdravkovic, M
    Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers
    JOURNAL OF CLINICAL PHARMACOLOGY
    
    H. Agerso et al., "Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers", J CLIN PHAR, 41(2), 2001, pp. 163-169
36. Burns, HD; Hamill, TG; Eng, WS; Hargreaves, R
    Chapter 26. PET ligands for assessing receptor occupancy in vivo
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 36
    
    H.D. Burns et al., "Chapter 26. PET ligands for assessing receptor occupancy in vivo", ANNU REP M, 36, 2001, pp. 267-276
37. Scolnick, EM; Slater, EE; Williams, GW
    "Natural history" clinical trials: An enduring contribution to modern medical practice
    ADVANCES IN PROTEIN CHEMISTRY, VOL 56
    
    E.M. Scolnick et al., ""Natural history" clinical trials: An enduring contribution to modern medical practice", ADV PROTEIN, 56, 2001, pp. 1-12
38. Sass, HM
    Do we need new clnical ethical models in medical research?
    WIENER KLINISCHE WOCHENSCHRIFT
    
    H.M. Sass, "Do we need new clnical ethical models in medical research?", WIEN KLIN W, 113(22), 2001, pp. 863-866
39. Marona, H; Pekala, E; Filipek, B; Maciag, D; Szneler, E
    Pharmacological properties of some aminoalkanolic derivatives of xanthone
    PHARMAZIE
    
    H. Marona et al., "Pharmacological properties of some aminoalkanolic derivatives of xanthone", PHARMAZIE, 56(7), 2001, pp. 567-572
40. Pandeya, SN; Sriram, D; Yogeeswari, P; Stables, JP
    Anticonvulsant and neurotoxicity evaluation of 5-(un)-substituted isatinimino derivatives
    PHARMAZIE
    
    S.N. Pandeya et al., "Anticonvulsant and neurotoxicity evaluation of 5-(un)-substituted isatinimino derivatives", PHARMAZIE, 56(11), 2001, pp. 875-876
41. Kennedy, MA
    What does the human genome project mean for medicine?
    NEW ZEALAND MEDICAL JOURNAL
    
    M.A. Kennedy, "What does the human genome project mean for medicine?", NZ MED J, 114(1130), 2001, pp. 190-192
42. Fischer, W; Kittner, H; Regenthal, R; Malinowska, B; Schlicker, E
    Anticonvulsant and sodium channel blocking activity of higher doses of clenbuterol
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
    
    W. Fischer et al., "Anticonvulsant and sodium channel blocking activity of higher doses of clenbuterol", N-S ARCH PH, 363(2), 2001, pp. 182-192
43. Kinghorn, AD
    Pharmacognosy in the 21st century
    JOURNAL OF PHARMACY AND PHARMACOLOGY
    
    A.D. Kinghorn, "Pharmacognosy in the 21st century", J PHARM PHA, 53(2), 2001, pp. 135-148
44. Srinivas, NR; Barbhaiya, RH; Midha, KK
    Enantiomeric drug development: Issues, considerations, and regulatory requirements
    JOURNAL OF PHARMACEUTICAL SCIENCES
    
    N.R. Srinivas et al., "Enantiomeric drug development: Issues, considerations, and regulatory requirements", J PHARM SCI, 90(9), 2001, pp. 1205-1215
45. Steegborn, C; Laber, B; Messerschmidt, A; Huber, R; Clausen, T
    Crystal structures of cystathionine gamma-synthase inhibitor complexes rationalize the increased affinity of a novel inhibitor
    JOURNAL OF MOLECULAR BIOLOGY
    
    C. Steegborn et al., "Crystal structures of cystathionine gamma-synthase inhibitor complexes rationalize the increased affinity of a novel inhibitor", J MOL BIOL, 311(4), 2001, pp. 789-801
46. Versees, W; Decanniere, K; Pelle, R; Depoorter, J; Brosens, E; Parkin, DW; Steyaert, J
    Structure and function of a novel purine specific nucleoside hydrolase from Trypanosoma vivax
    JOURNAL OF MOLECULAR BIOLOGY
    
    W. Versees et al., "Structure and function of a novel purine specific nucleoside hydrolase from Trypanosoma vivax", J MOL BIOL, 307(5), 2001, pp. 1363-1379
47. Madsen, U; Brauner-Osborne, H; Frydenvang, K; Hvene, L; Johansen, TN; Nielsen, B; Sanchez, C; Stensbol, TB; Bischoff, F; Krogsgaard-Larsen, P
    Synthesis and pharmacology of 3-isoxazolol amino acids as selective antagonists at group I metabotropic glutamic acid receptors
    JOURNAL OF MEDICINAL CHEMISTRY
    
    U. Madsen et al., "Synthesis and pharmacology of 3-isoxazolol amino acids as selective antagonists at group I metabotropic glutamic acid receptors", J MED CHEM, 44(7), 2001, pp. 1051-1059
48. Swann, E; Barraja, P; Oberlander, AM; Gardipee, WT; Hudnott, AR; Beall, HD; Moody, CJ
    Indolequinone antitumor agents: Correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H : quinone oxidoreductase. Part 2
    JOURNAL OF MEDICINAL CHEMISTRY
    
    E. Swann et al., "Indolequinone antitumor agents: Correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H : quinone oxidoreductase. Part 2", J MED CHEM, 44(20), 2001, pp. 3311-3319
49. Blanchet, JS; Valmori, D; Dufau, I; Ayyoub, M; Nguyen, C; Guillaume, P; Monsarrat, B; Cerottini, JC; Romero, P; Gairin, JE
    A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: Implication for molecular anti-melanoma immunotherapy
    JOURNAL OF IMMUNOLOGY
    
    J.S. Blanchet et al., "A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: Implication for molecular anti-melanoma immunotherapy", J IMMUNOL, 167(10), 2001, pp. 5852-5861
50. Vis, P; Della Pasqua, O; Kruk, M; Martin, D; Mocaer, E; Danhof, M; Jochemsen, R
    Population pharmacokinetic-pharmacodynamic modelling of S 15535, a 5-MT1A receptor agonist, using a behavioural model in rats
    EUROPEAN JOURNAL OF PHARMACOLOGY
    
    P. Vis et al., "Population pharmacokinetic-pharmacodynamic modelling of S 15535, a 5-MT1A receptor agonist, using a behavioural model in rats", EUR J PHARM, 414(2-3), 2001, pp. 233-243
51. Stensbol, TB; Jensen, HS; Nielsen, B; Johansen, TN; Egebjerg, J; Frydenvang, K; Krogsgaard-Larsen, P
    Stereochemistry and molecular pharmacology of (S)-thio-ATPA, a new potent and selective GluR5 agonist
    EUROPEAN JOURNAL OF PHARMACOLOGY
    
    T.B. Stensbol et al., "Stereochemistry and molecular pharmacology of (S)-thio-ATPA, a new potent and selective GluR5 agonist", EUR J PHARM, 411(3), 2001, pp. 245-253
52. Kurup, A; Garg, R; Hansch, C
    Comparative QSAR study of tyrosine kinase inhibitors
    CHEMICAL REVIEWS
    
    A. Kurup et al., "Comparative QSAR study of tyrosine kinase inhibitors", CHEM REV, 101(8), 2001, pp. 2573-2600
53. Parker, TJ; Della Pasqua, OE; Loizillon, E; Chezaubernard, C; Jochemsen, R; Danhof, M
    Pharmacokinetic-pharmacodynamic modelling in the early development phase of anti-psychotics: A comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats
    BRITISH JOURNAL OF PHARMACOLOGY
    
    T.J. Parker et al., "Pharmacokinetic-pharmacodynamic modelling in the early development phase of anti-psychotics: A comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats", BR J PHARM, 132(1), 2001, pp. 151-158
54. Choudry, GA; Stewart, PAH; Double, JA; Krul, MRL; Naylor, B; Flannigan, GM; Shah, TK; Brown, JE; Phillips, RM
    A novel strategy for NQO1 (NAD(P)H : quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9
    BRITISH JOURNAL OF CANCER
    
    G.A. Choudry et al., "A novel strategy for NQO1 (NAD(P)H : quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9", BR J CANC, 85(8), 2001, pp. 1137-1146
55. Green, MF; Braff, DL
    Translating the basic and clinical cognitive neuroscience of schizophreniato drug development and clinical trials of antipsychotic medications
    BIOLOGICAL PSYCHIATRY
    
    M.F. Green e D.L. Braff, "Translating the basic and clinical cognitive neuroscience of schizophreniato drug development and clinical trials of antipsychotic medications", BIOL PSYCHI, 49(4), 2001, pp. 374-384
56. Clarke, PA; Poele, RT; Wooster, R; Workman, P
    Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential
    BIOCHEMICAL PHARMACOLOGY
    
    P.A. Clarke et al., "Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential", BIOCH PHARM, 62(10), 2001, pp. 1311-1336
57. Phillips, RM; Burger, AM; Fiebig, HH; Double, JA
    Genotyping of NAD(P)H : quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo
    BIOCHEMICAL PHARMACOLOGY
    
    R.M. Phillips et al., "Genotyping of NAD(P)H : quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo", BIOCH PHARM, 62(10), 2001, pp. 1371-1377
58. Winski, SL; Swann, E; Hargreaves, RHJ; Dehn, DL; Butler, J; Moody, CJ; Ross, D
    Relationship between NAD(P)H : quinone oxidoreductase 1 (NQO1) levels in aseries of stably transfected cell lines and susceptibility to antitumor quinones
    BIOCHEMICAL PHARMACOLOGY
    
    S.L. Winski et al., "Relationship between NAD(P)H : quinone oxidoreductase 1 (NQO1) levels in aseries of stably transfected cell lines and susceptibility to antitumor quinones", BIOCH PHARM, 61(12), 2001, pp. 1509-1516
59. Palom, Y; Belcourt, MF; Tang, LQ; Mehta, SS; Sartorelli, AC; Pritsos, CA; Pritsos, KL; Rockwell, S; Tomasz, M
    Bioreductive metabolism of mitomycin C in EMT6 mouse mammary tumor cells: cytotoxic and non-cytotoxic pathways, leading to different types of DNA adducts. The effect of dicumarol
    BIOCHEMICAL PHARMACOLOGY
    
    Y. Palom et al., "Bioreductive metabolism of mitomycin C in EMT6 mouse mammary tumor cells: cytotoxic and non-cytotoxic pathways, leading to different types of DNA adducts. The effect of dicumarol", BIOCH PHARM, 61(12), 2001, pp. 1517-1529
60. Beckmann, N; Mueggler, T; Allegrini, PR; Laurent, D; Rudin, M
    From anatomy to the target: Contributions of magnetic resonance imaging topreclinical pharmaceutical research
    ANATOMICAL RECORD
    
    N. Beckmann et al., "From anatomy to the target: Contributions of magnetic resonance imaging topreclinical pharmaceutical research", ANAT REC, 265(2), 2001, pp. 85-100
61. Bartenschlager, R; Lohmann, V
    Replication of the hepatitis C virus
    BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
    
    R. Bartenschlager e V. Lohmann, "Replication of the hepatitis C virus", BEST PR RES, 14(2), 2000, pp. 241-254
62. Cummings, J
    The role of reductive enzymes in cancer cell resistance to mitomycin C
    DRUG RESISTANCE UPDATES
    
    J. Cummings, "The role of reductive enzymes in cancer cell resistance to mitomycin C", DRUG RESIST, 3(3), 2000, pp. 143-148
63. Destenaves, B; Thomas, F
    New advances in pharmacogenomics
    CURRENT OPINION IN CHEMICAL BIOLOGY
    
    B. Destenaves e F. Thomas, "New advances in pharmacogenomics", CURR OP C B, 4(4), 2000, pp. 440-444
64. Jain, KK
    An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development
    EXPERT OPINION ON INVESTIGATIONAL DRUGS
    
    K.K. Jain, "An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development", EXPERT OP I, 9(4), 2000, pp. 829-840
65. Gribaldo, L; Malerba, I; Collotta, A; Casati, S; Pessina, A
    Inhibition of CFU-E/BFU-E by 3 '-azido-3 '-deoxythymidine, chlorpropamide,and protoporphirin IX zinc (II): A comparison between direct exposure of progenitor cells and long-term exposure of bone marrow cultures
    TOXICOLOGICAL SCIENCES
    
    L. Gribaldo et al., "Inhibition of CFU-E/BFU-E by 3 '-azido-3 '-deoxythymidine, chlorpropamide,and protoporphirin IX zinc (II): A comparison between direct exposure of progenitor cells and long-term exposure of bone marrow cultures", TOXICOL SCI, 58(1), 2000, pp. 96-101
66. Dean, NM; Cooper, SR; Shanahan, W; Taylor, J; Myers, K
    Pharmacology of antisense oligonucleotides
    JOURNAL OF CLINICAL LIGAND ASSAY
    
    N.M. Dean et al., "Pharmacology of antisense oligonucleotides", J CLIN LIG, 23(1), 2000, pp. 43-49
67. Agarwal, C; Sharma, Y; Zhao, JF; Agarwal, R
    A polyphenolic fraction from grape seeds causes irreversible growth inhibition of breast carcinoma MDA-MB468 cells by inhibiting mitogen-activated protein kinases activation and inducing G(1) arrest and differentiation
    CLINICAL CANCER RESEARCH
    
    C. Agarwal et al., "A polyphenolic fraction from grape seeds causes irreversible growth inhibition of breast carcinoma MDA-MB468 cells by inhibiting mitogen-activated protein kinases activation and inducing G(1) arrest and differentiation", CLIN CANC R, 6(7), 2000, pp. 2921-2930
68. Cox, K
    Enhancing cancer clinical trial management: Recommendations from a qualitative study of trial participants' experiences
    PSYCHO-ONCOLOGY
    
    K. Cox, "Enhancing cancer clinical trial management: Recommendations from a qualitative study of trial participants' experiences", PSYCHO-ONC, 9(4), 2000, pp. 314-322
69. Novack, GD
    Financing new drug development in ophthalmology
    JOURNAL OF GLAUCOMA
    
    G.D. Novack, "Financing new drug development in ophthalmology", J GLAUCOMA, 9(2), 2000, pp. 195-199
70. Cunningham, MJ
    Genomics and proteomics - The new millennium of drug discovery and development
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
    
    M.J. Cunningham, "Genomics and proteomics - The new millennium of drug discovery and development", J PHARM TOX, 44(1), 2000, pp. 291-300
71. Gralinski, MR
    The assessment of potential for QT interval prolongation with new pharmaceuticals Impact on drug development
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
    
    M.R. Gralinski, "The assessment of potential for QT interval prolongation with new pharmaceuticals Impact on drug development", J PHARM TOX, 43(2), 2000, pp. 91-99
72. Price, P
    Monitoring response to treatment in the development of anticancer drugs using PET
    NUCLEAR MEDICINE AND BIOLOGY
    
    P. Price, "Monitoring response to treatment in the development of anticancer drugs using PET", NUCL MED BI, 27(7), 2000, pp. 691-691
73. Andree, B; Halldin, C; Thorberg, SO; Sandell, J; Farde, L
    Use of PET and the radioligand [Carbonyl-C-11]WAY-100635 in psychotropic drug development
    NUCLEAR MEDICINE AND BIOLOGY
    
    B. Andree et al., "Use of PET and the radioligand [Carbonyl-C-11]WAY-100635 in psychotropic drug development", NUCL MED BI, 27(5), 2000, pp. 515-521
74. Estrada, E; Pena, A
    In silico studies for the rational discovery of anticonvulsant compounds
    BIOORGANIC & MEDICINAL CHEMISTRY
    
    E. Estrada e A. Pena, "In silico studies for the rational discovery of anticonvulsant compounds", BIO MED CH, 8(12), 2000, pp. 2755-2770
75. Otvos, L; Bokonyi, K; Varga, I; Otvos, BI; Hoffmann, R; Ertl, HCJ; Wade, JD; McManus, AM; Craik, D; Bulet, P
    Insect peptides with improved protease-resistance protect mice against bacterial infection
    PROTEIN SCIENCE
    
    L. Otvos et al., "Insect peptides with improved protease-resistance protect mice against bacterial infection", PROTEIN SCI, 9(4), 2000, pp. 742-749
76. Jonsson, E; Dhar, S; Jonsson, B; Nygren, P; Graf, W; Larsson, R
    Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines
    EUROPEAN JOURNAL OF CANCER
    
    E. Jonsson et al., "Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines", EUR J CANC, 36(16), 2000, pp. 2120-2127
77. Pryor, JL; Redmon, B
    New therapies and delivery mechanisms for treatment of erectile dysfunction
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
    
    J.L. Pryor e B. Redmon, "New therapies and delivery mechanisms for treatment of erectile dysfunction", INT J IMPOT, 12, 2000, pp. S158-S162
78. Heinrich, M
    Ethnobotany and its role in drug development
    PHYTOTHERAPY RESEARCH
    
    M. Heinrich, "Ethnobotany and its role in drug development", PHYTOTHER R, 14(7), 2000, pp. 479-488
79. Al-Obeidi, FA; Lam, KS
    Development of inhibitors for protein tyrosine kinases
    ONCOGENE
    
    F.A. Al-Obeidi e K.S. Lam, "Development of inhibitors for protein tyrosine kinases", ONCOGENE, 19(49), 2000, pp. 5690-5701
80. Balant, LP; Balant-Gorgia, EA
    Cultural differences: implications on drug therapy and global drug development
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    
    L.P. Balant e E.A. Balant-Gorgia, "Cultural differences: implications on drug therapy and global drug development", INT J CL PH, 38(2), 2000, pp. 47-52
81. Nagata, R; Fukase, H; Rafizadeh-Kabe, JD
    East-West development: understanding the usability and acceptance of foreign data in Japan
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    
    R. Nagata et al., "East-West development: understanding the usability and acceptance of foreign data in Japan", INT J CL PH, 38(2), 2000, pp. 87-92
82. Argenti, D; Vaccaro, SK; Shah, B; Gillen, MS; Rohatagi, S; Jensen, BK
    Effect of food and gender on the pharmacokinetics of RP 73401, a phosphodiesterase IV inhibitor
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    
    D. Argenti et al., "Effect of food and gender on the pharmacokinetics of RP 73401, a phosphodiesterase IV inhibitor", INT J CL PH, 38(12), 2000, pp. 588-594
83. Smith, DA
    Induction and drug development
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
    
    D.A. Smith, "Induction and drug development", EUR J PH SC, 11(3), 2000, pp. 185-189
84. Whitehouse, PJ
    Harmonization of dementia drug guidelines (United States and Europe): A report of the International Working Group for the Harmonization for Dementia Drug Guidelines
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS
    
    P.J. Whitehouse, "Harmonization of dementia drug guidelines (United States and Europe): A report of the International Working Group for the Harmonization for Dementia Drug Guidelines", ALZ DIS A D, 14, 2000, pp. S119-S122
85. Janero, DR; Ewing, JF
    Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential
    FREE RADICAL BIOLOGY AND MEDICINE
    
    D.R. Janero e J.F. Ewing, "Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential", FREE RAD B, 29(12), 2000, pp. 1199-1221
86. Janero, DR
    Nitric oxide (NO)-related pharmaceuticals: Contemporary approaches to therapeutic NO modulation
    FREE RADICAL BIOLOGY AND MEDICINE
    
    D.R. Janero, "Nitric oxide (NO)-related pharmaceuticals: Contemporary approaches to therapeutic NO modulation", FREE RAD B, 28(10), 2000, pp. 1495-1506
87. Findlay, JWA; Smith, WC; Lee, JW; Nordblom, GD; Das, I; DeSilva, BS; Khan, MN; Bowsher, RR
    Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    
    J.W.A. Findlay et al., "Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective", J PHARM B, 21(6), 2000, pp. 1249-1273
88. Brenner, DE
    Multiagent chemopreventive agent combinations
    JOURNAL OF CELLULAR BIOCHEMISTRY
    
    D.E. Brenner, "Multiagent chemopreventive agent combinations", J CELL BIOC, 2000, pp. 121-124
89. Weihrauch, TR
    Career opportunities for physicians in the pharmaceutical industry
    MEDIZINISCHE KLINIK
    
    T.R. Weihrauch, "Career opportunities for physicians in the pharmaceutical industry", MED KLIN, 95(6), 2000, pp. 322-326
90. Kuhlmann, J
    Tasks of clinical pharmacology in the early phase of drug development
    MEDIZINISCHE KLINIK
    
    J. Kuhlmann, "Tasks of clinical pharmacology in the early phase of drug development", MED KLIN, 95, 2000, pp. 31-40
91. Gieschke, R; Steimer, JL
    Pharmacometrics: modelling and simulation tools to improve decision makingin clinical drug development
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
    
    R. Gieschke e J.L. Steimer, "Pharmacometrics: modelling and simulation tools to improve decision makingin clinical drug development", EUR J DRUG, 25(1), 2000, pp. 49-58
92. Panchagnula, R; Thomas, NS
    Biopharmaceutics and pharmacokinetics in drug research
    INTERNATIONAL JOURNAL OF PHARMACEUTICS
    
    R. Panchagnula e N.S. Thomas, "Biopharmaceutics and pharmacokinetics in drug research", INT J PHARM, 201(2), 2000, pp. 131-150
93. Holford, NHG; Kimko, HC; Monteleone, JPR; Peck, CC
    Simulation of clinical trials
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
    
    N.H.G. Holford et al., "Simulation of clinical trials", ANN R PHARM, 40, 2000, pp. 209-234
94. Arledge, T; Freeman, A; Arbuckle, J; Mosteller, M; Manasco, P
    Applications of pharmacogenetics to drug development: The Glaxo Wellcome experience
    DRUG METABOLISM REVIEWS
    
    T. Arledge et al., "Applications of pharmacogenetics to drug development: The Glaxo Wellcome experience", DRUG METAB, 32(3-4), 2000, pp. 387-394
95. Adams, DJ; Dewhirst, MW; Flowers, JL; Gamcsik, MP; Colvin, OM; Manikumar, G; Wani, MC; Wall, ME
    Camptothecin analogues with enhanced antitumor activity at acidic pH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    D.J. Adams et al., "Camptothecin analogues with enhanced antitumor activity at acidic pH", CANC CHEMOT, 46(4), 2000, pp. 263-271
96. Fuhrman, S; Cunningham, MJ; Wen, XL; Zweiger, G; Seilhamer, JJ; Somogyi, R
    The application of Shannon entropy in the identification of putative drug targets
    BIOSYSTEMS
    
    S. Fuhrman et al., "The application of Shannon entropy in the identification of putative drug targets", BIOSYSTEMS, 55(1-3), 2000, pp. 5-14
97. Zisapel, N
    Development of a melatonin-based formulation for the treatment of insomniain the elderly
    DRUG DEVELOPMENT RESEARCH
    
    N. Zisapel, "Development of a melatonin-based formulation for the treatment of insomniain the elderly", DRUG DEV R, 50(3-4), 2000, pp. 226-234
98. Fry, DW
    Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer
    ANTI-CANCER DRUG DESIGN
    
    D.W. Fry, "Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer", ANTI-CAN DR, 15(1), 2000, pp. 3-16
99. Pandeya, SN; Yogeeswari, P; Stables, JP
    Synthesis and anticonvulsant activity of 4-bromophenyl substituted aryl semicarbazones
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
    
    S.N. Pandeya et al., "Synthesis and anticonvulsant activity of 4-bromophenyl substituted aryl semicarbazones", EUR J MED C, 35(10), 2000, pp. 879-886
100. Sanger-van de Griend, CE
     Enantiomeric separation of alanyl and leucyl dipeptides by capillary electrophoresis with cyclodextrins as chiral selectors
     ELECTROPHORESIS
     
     C.E. Sanger-van de Griend, "Enantiomeric separation of alanyl and leucyl dipeptides by capillary electrophoresis with cyclodextrins as chiral selectors", ELECTROPHOR, 21(12), 2000, pp. 2397-2404